Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Marlies Ostermann, Rinaldo Bellomo, Emmanuel A Burdmann, Kent Doi, Zoltan H Endre, Stuart L Goldstein, Sandra L Kane-Gill, Kathleen D Liu, John R Prowle, Andrew D Shaw, Nattachai Srisawat, Michael Cheung, Michel Jadoul, Wolfgang C Winkelmayer, John A Kellum, Conference Participants, Sean M Bagshaw, Erin F Barreto, Azra Bihorac, Ilona Bobek, Josée Bouchard, Jorge Cerdá, Rajasekara Chakravarthi, Silvia De Rosa, Daniel T Engelman, Lui G Forni, Ulla K Hemmilä, Charles A Herzog, Eric A Hoste, Sarah C Huen, Kunitoshi Iseki, Michael Joannidis, Kianoush B Kashani, Jay L Koyner, Andreas Kribben, Norbert Lameire, Andrew S Levey, Etienne Macedo, Jolanta Małyszko, Melanie Meersch, Ravindra L Mehta, Irene Mewburn, Olga Mironova, Patrick T Murray, Mitra K Nadim, Jenny S Pan, Neesh Pannu, Zhiyong Peng, Barbara Philips, Daniela Ponce, Patricio E Ray, Zaccaria Ricci, Thomas Rimmelé, Claudio Ronco, Edward D Siew, Paul E Stevens, Ashita J Tolwani, Marcello Tonelli, Suvi T Vaara, Marjel van Dam, Anitha Vijayan, Michael Wise, Vin-Cent Wu, Alexander Zarbock, Marlies Ostermann, Rinaldo Bellomo, Emmanuel A Burdmann, Kent Doi, Zoltan H Endre, Stuart L Goldstein, Sandra L Kane-Gill, Kathleen D Liu, John R Prowle, Andrew D Shaw, Nattachai Srisawat, Michael Cheung, Michel Jadoul, Wolfgang C Winkelmayer, John A Kellum, Conference Participants, Sean M Bagshaw, Erin F Barreto, Azra Bihorac, Ilona Bobek, Josée Bouchard, Jorge Cerdá, Rajasekara Chakravarthi, Silvia De Rosa, Daniel T Engelman, Lui G Forni, Ulla K Hemmilä, Charles A Herzog, Eric A Hoste, Sarah C Huen, Kunitoshi Iseki, Michael Joannidis, Kianoush B Kashani, Jay L Koyner, Andreas Kribben, Norbert Lameire, Andrew S Levey, Etienne Macedo, Jolanta Małyszko, Melanie Meersch, Ravindra L Mehta, Irene Mewburn, Olga Mironova, Patrick T Murray, Mitra K Nadim, Jenny S Pan, Neesh Pannu, Zhiyong Peng, Barbara Philips, Daniela Ponce, Patricio E Ray, Zaccaria Ricci, Thomas Rimmelé, Claudio Ronco, Edward D Siew, Paul E Stevens, Ashita J Tolwani, Marcello Tonelli, Suvi T Vaara, Marjel van Dam, Anitha Vijayan, Michael Wise, Vin-Cent Wu, Alexander Zarbock

Abstract

In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on the classification and management of acute kidney injury (AKI). The guideline was derived from evidence available through February 2011. Since then, new evidence has emerged that has important implications for clinical practice in diagnosing and managing AKI. In April of 2019, KDIGO held a controversies conference entitled Acute Kidney Injury with the following goals: determine best practices and areas of uncertainty in treating AKI; review key relevant literature published since the 2012 KDIGO AKI guideline; address ongoing controversial issues; identify new topics or issues to be revisited for the next iteration of the KDIGO AKI guideline; and outline research needed to improve AKI management. Here, we present the findings of this conference and describe key areas that future guidelines may address.

Keywords: acute kidney disease; acute kidney injury; fluid management; nephrotoxicity; renal replacement therapy; risk stratification.

Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1 |. Schematic for acute kidney…
Figure 1 |. Schematic for acute kidney injury/acute kidney diseases and disorders (AKI/AKD) follow-up.
The figure displays a potential paradigm for the care of patients who experience AKI/AKD. The degree of nephrology-based follow-up increases as the duration and severity of AKI/AKD increases. The timing and nature of follow-up are suggestions, as there are limited data to inform this process. Future research efforts should work to clarify the timing of AKI/AKD follow-up and which specific healthcare providers should provide it. The items in each bucket follow the “OR” rule; therefore, each patient should follow the most-severe bucket even if they meet only 1 criterion in that bucket. For example, a patient with CKD G4, regardless of severity of AKI, should be followed by a nephrologist in 1 week. AKI stage 3D, AKI stage 3 treated by dialysis; CKD, chronic kidney disease; CV, cardiovascular; dx, diagnosis; KAMPS, kidney function–advocacy–medications–pressure–sick day protocol; SCr, serum creatinine; UA, urine analysis; WATCH-ME, weight assessment–access–teaching–clearance–hypotension–medications. Reproduced with permission under a Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0) from Acute Dialysis Quality Initiative. Quality improvement goals for acute kidney injury; ADQI XXII. Available at: https://www.adqi.org/Images_Charts-Call.htm. Accessed June 14, 2020.
Figure 2 |. Classifying drugs that potentially…
Figure 2 |. Classifying drugs that potentially cause acute kidney injury.
Iterative classification of agents that have potential to cause kidney dysfunction or kidney injury or both. Functional and injury biomarkers have a role in distinguishing among the different pathophysiological processes. Examples of deleterious risk modifiers are duration of therapy, drug burden, hypotension, and pharmacokinetic/pharmacodynamic interactions. Examples of interventions to mitigate risk are daily dynamic prescribing, kidney monitoring, and patient and provider education. Susceptibility factors include those listed in the 2012 Kidney Disease: Improving Global Outcomes Acute Kidney Injury guideline: dehydration or volume depletion; advanced age; female gender; black race; chronic kidney disease; chronic diseases of the heart, lung, or liver; diabetes mellitus; cancer; and anemia. Any final impact depends on underlying susceptibility, associated risk factors, clinical context, drug management, and modifying factors. Examples of drugs that correspond to the relevant categories above include trimethoprim, cimetidine (neither dysfunction nor injury); angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers (dysfunction without injury); aminoglycoside, acyclovir, vascular endothelial growth factor antagonists (injury without dysfunction); and nonsteroidal anti-inflammatory drugs (dysfunction and injury).
Figure 3 |
Figure 3 |
Schematic diagram of renal replacement therapy (RRT) decisions in acute kidney injury (AKI).

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2:1–138.
    1. Hoste EA, Bagshaw SM, Bellomo R, et al.Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41:1411–1423.
    1. Mehta RL, Cerda J, Burdmann EA, et al.International Society of Nephrology’s 0-by-25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. 2015;385:2616–2643.
    1. Srisawat N, Kulvichit W, Mahamitra N, et al.The epidemiology and characteristics of acute kidney injury in the Southeast Asia intensive care unit: a prospective multicentre study. Nephrol Dial Transplant. 2019. pii: gfz087. Accessed June 14, 2020.
    1. Kaddourah A, Basu RK, Bagshaw SM, et al.Epidemiology of acute kidney injury in critically ill children and young adults. N Engl J Med. 2017;376:11–20.
    1. Jetton JG, Boohaker LJ, Sethi SK, et al.Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study. Lancet Child Adolesc Health. 2017;1:184–194.
    1. Meersch M, Schmidt C, Hoffmeier A, et al.Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43:1551–1561.
    1. Gocze I, Jauch D, Gotz M, et al.Biomarker-guided intervention to prevent acute kidney injury after major surgery: the prospective randomized BigpAK Study. Ann Surg. 2018;267:1013–1020.
    1. Kellum JA, Chawla LS, Keener C, et al.The effects of alternative resuscitation strategies on acute kidney injury in patients with septic shock. Am J Respir Crit Care Med. 2016;193:281–287.
    1. Nijssen EC, Rennenberg RJ, Nelemans PJ, et al.Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389:1312–1322.
    1. Self WH, Semler MW, Wanderer JP, et al.Balanced crystalloids versus saline in noncritically ill adults. N Engl J Med. 2018;378:819–828.
    1. Semler MW, Self WH, Wanderer JP, et al.Balanced crystalloids versus saline in critically ill adults. N Engl J Med. 2018;378:829–839.
    1. Zarbock A, Kellum JA, Schmidt C, et al.Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: The ELAIN Randomized Clinical Trial. JAMA. 2016;315:2190–2199.
    1. Gaudry S, Hajage D, Schortgen F, et al.Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375:122–133.
    1. Barbar SD, Clere-Jehl R, Bourredjem A, et al.Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N Engl J Med. 2018;379:1431–1442.
    1. Al-Jaghbeer M, Dealmeida D, Bilderback A, et al.Clinical decision support for in-hospital AKI. J Am Soc Nephrol. 2018;29:654–660.
    1. Selby NM, Casula A, Lamming L, et organizational-level program of intervention for AKI: a pragmatic stepped wedge cluster randomized trial. J Am Soc Nephrol. 2019;30:505–515.
    1. Tollitt J, Flanagan E, McCorkindale S, et al.Improved management of acute kidney injury in primary care using e-alerts and an educational outreach programme. Fam Pract. 2018;35:684–689.
    1. Wilson FP, Shashaty M, Testani J, et al.Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. Lancet. 2015;385:1966–1974.
    1. Kolhe NV, Staples D, Reilly T, et al.Impact of compliance with a care bundle on acute kidney injury outcomes: a prospective observational study. PLoS One. 2015;10:e0132279.
    1. Goldstein SL, Mottes T, Simpson K, et al.A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury. Kidney Int. 2016;90:212–221.
    1. Haase M, Bellomo R, Devarajan P, et al.Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54:1012–1024.
    1. Kashani K, Al-Khafaji A, Ardiles T, et al.Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17:R25.
    1. Bihorac A, Chawla LS, Shaw AD, et al.Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med. 2014;189:932–939.
    1. Guzzi LM, Bergler T, Binnall B, et al.Clinical use of [TIMP-2]*[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel. Crit Care. 2019;23:225.
    1. Sparrow HG, Swan JT, Moore LW, et al.Disparate outcomes observed within Kidney Disease: Improving Global Outcomes (KDIGO) acute kidney injury stage 1. Kidney Int. 2019;95:905–913.
    1. Barasch J, Zager R, Bonventre JV. Acute kidney injury: a problem of definition. Lancet. 2017;389:779–781.
    1. James MT, Levey AS, Tonelli M, et al.Incidence and prognosis of acute kidney diseases and disorders using an integrated approach to laboratory measurements in a universal health care system. JAMA Netw Open. 2019;2:e191795.
    1. Kellum JA, Sileanu FE, Murugan R, et al.Classifying AKI by urine output versus serum creatinine level. J Am Soc Nephrol. 2015;26:2231–2238.
    1. Allen JC, Gardner DS, Skinner H, et al.Definition of hourly urine output influences reported incidence and staging of acute kidney injury. BMC Nephrol. 2020;21:19.
    1. Kashani K, Rosner MH, Haase M, et al.Quality improvement goals for acute kidney injury. Clin J Am Soc Nephrol. 2019;14:941–953.
    1. Engelman DT, Ben Ali W, Williams JB, et al.Guidelines for perioperative care in cardiac surgery: enhanced recovery after surgery society recommendations. JAMA Surg. 2019;154:755–766.
    1. Park S, Baek SH, Ahn S, et al.Impact of electronic acute kidney injury (AKI) alerts with automated nephrologist consultation on detection and severity of AKI: a quality improvement study. Am J Kidney Dis. 2018;71:9–19.
    1. Koyner JL, Carey KA, Edelson DP, et al.The development of a machine learning inpatient acute kidney injury prediction model. Crit Care Med. 2018;46:1070–1077.
    1. Bihorac A, Ozrazgat-Baslanti T, Ebadi A, et al.MySurgeryRisk: development and validation of a machine-learning risk algorithm for major complications and death after surgery. Ann Surg. 2019;269:652–662.
    1. Tomasev N, Glorot X, Rae JW, et al.A clinically applicable approach to continuous prediction of future acute kidney injury. Nature. 2019;572:116–119.
    1. Matsuura R, Srisawat N, Claure-Del Granado R, et al.Use of the Renal Angina Index in determining acute kidney injury. Kidney Int Rep. 2018;3:677–683.
    1. Basu RK, Kaddourah A, Goldstein SL, et al.Assessment of a renal angina index for prediction of severe acute kidney injury in critically ill children: a multicentre, multinational, prospective observational study. Lancet Child Adolesc Health. 2018;2:112–120.
    1. Koyner JL, Davison DL, Brasha-Mitchell E, et al.Furosemide stress test and biomarkers for the prediction of AKI severity. J Am Soc Nephrol. 2015;26:2023–2031.
    1. Kerr KF, Meisner A, Thiessen-Philbrook H, et al.Developing risk prediction models for kidney injury and assessing incremental value for novel biomarkers. Clin J Am Soc Nephrol. 2014;9:1488–1496.
    1. Wang JJ, Chi NH, Huang TM, et al.Urinary biomarkers predict advanced acute kidney injury after cardiovascular surgery. Crit Care. 2018;22:108.
    1. Basu RK, Wong HR, Krawczeski CD, et al.Combining functional and tubular damage biomarkers improves diagnostic precision for acute kidney injury after cardiac surgery. J Am Coll Cardiol. 2014;64:2753–2762.
    1. Bhatraju PK, Zelnick LR, Katz R, et al.A prediction model for severe AKI in critically ill adults that incorporates clinical and biomarker data. Clin J Am Soc Nephrol. 2019;14:506–514.
    1. Chawla LS, Bellomo R, Bihorac A, et al.Acute kidney disease and renal recovery consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241–257.
    1. Waikar SS, McMahon GM. Expanding the role for kidney biopsies in acute kidney injury. Semin Nephrol. 2018;38:12–20.
    1. Hull TD, Agarwal A, Hoyt K. New ultrasound techniques promise further advances in AKI and CKD. J Am Soc Nephrol. 2017;28:3452–3460.
    1. Meola M, Nalesso F, Petrucci I, et al.Ultrasound in acute kidney disease. Contrib Nephrol. 2016;188:11–20.
    1. Zhou HY, Chen TW, Zhang XM. Functional magnetic resonance imaging in acute kidney injury: present status. Biomed Res Int. 2016;2016:2027370.
    1. Perazella MA, Coca SG. Traditional urinary biomarkers in the assessment of hospital-acquired AKI. Clin J Am Soc Nephrol. 2012;7:167–174.
    1. Bagshaw SM, Haase M, Haase-Fielitz A, et al.A prospective evaluation of urine microscopy in septic and non-septic acute kidney injury. Nephrol Dial Transplant. 2012;27:582–588.
    1. Bagshaw SM, Bennett M, Devarajan P, et al.Urine biochemistry in septic and non-septic acute kidney injury: a prospective observational study. J Crit Care. 2013;28:371–378.
    1. Chawla LS, Davison DL, Brasha-Mitchell E, et al.Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care. 2013;17:R207.
    1. McMahon BA, Koyner JL, Novick T, et al.The prognostic value of the furosemide stress test in predicting delayed graft function following deceased donor kidney transplantation. Biomarkers. 2018;23:61–69.
    1. Sawhney S, Mitchell M, Marks A, et al.Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review. BMJ Open. 2015;5:e006497.
    1. Wu VC, Wu PC, Wu CH, et al.The impact of acute kidney injury on the long-term risk of stroke. J Am Heart Assoc. 2014;3:e000933.
    1. Wu VC, Wu CH, Huang TM, et al.Long-term risk of coronary events after AKI. J Am Soc Nephrol. 2014;25:595–605.
    1. James MT, Pannu N, Hemmelgarn BR, et al.Derivation and external validation of prediction models for advanced chronic kidney disease following acute kidney injury. JAMA. 2017;318:1787–1797.
    1. Wald R, Kitchlu A, Harel Z, et al.Care of the acute kidney injury survivor. Nephron. 2017;137:306–309.
    1. Monnet X, Teboul JL. Assessment of fluid responsiveness: recent advances. Curr Opin Crit Care. 2018;24:190–195.
    1. Cecconi M, Hernandez G, Dunser M, et al.Fluid administration for acute circulatory dysfunction using basic monitoring: narrative review and expert panel recommendations from an ESICM task force. Intensive Care Med. 2019;45:21–32.
    1. Silversides JA, Major E, Ferguson AJ, et al.Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med. 2017;43:155–170.
    1. Self WH, Semler MW, Bellomo R, et al.Liberal versus restrictive intravenous fluid therapy for early septic shock: rationale for a randomized trial. Ann Emerg Med. 2018;72:457–466.
    1. Myles PS, Bellomo R, Corcoran T, et al.Restrictive versus liberal fluid therapy for major abdominal surgery. N Engl J Med. 2018;378:2263–2274.
    1. Pro CI, Yealy DM, Kellum JA, et al.A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370:1683–1693.
    1. ARISE Investigators; ANZICS Clinical Trials Group; Peake SL, et al.Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371:1496–1506.
    1. Mouncey PR, Osborn TM, Power GS, et al.Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372:1301–1311.
    1. Chong MA, Wang Y, Berbenetz NM, et al.Does goal-directed haemodynamic and fluid therapy improve peri-operative outcomes?: A systematic review and meta-analysis. Eur J Anaesthesiol. 2018;35:469–483.
    1. Corcoran T, Rhodes JE, Clarke S, et al.Perioperative fluid management strategies in major surgery: a stratified meta-analysis. Anesth Analg. 2012;114:640–651.
    1. Myburgh JA, Finfer S, Bellomo R, et al.Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367:1901–1911.
    1. Perner A, Haase N, Guttormsen AB, et al.Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012;367:124–134.
    1. Caironi P, Tognoni G, Masson S, et al.Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370:1412–1421.
    1. Martensson J, Bihari S, Bannard-Smith J, et al.Small volume resuscitation with 20% albumin in intensive care: physiological effects : The SWIPE randomised clinical trial. Intensive Care Med. 2018;44:1797–1806.
    1. Kingeter AJ, Raghunathan K, Munson SH, et al.Association between albumin administration and survival in cardiac surgery: a retrospective cohort study. Can J Anaesth. 2018;65:1218–1227.
    1. Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome. Hepatol Int. 2018;12:122–134.
    1. Martin GS, Moss M, Wheeler AP, et al.A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med. 2005;33:1681–1687.
    1. Claure-Del Granado R, Mehta RL. Fluid overload in the ICU: evaluation and management. BMC Nephrol. 2016;17:109.
    1. Mehta RL, Bouchard J. Controversies in acute kidney injury: effects of fluid overload on outcome. Contrib Nephrol. 2011;174:200–211.
    1. Raimundo M, Crichton S, Martin JR, et al.Increased fluid administration after early acute kidney injury is associated with less renal recovery. Shock. 2015;44:431–437.
    1. Sutherland SM, Zappitelli M, Alexander SR, et al.Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis. 2010;55:316–325.
    1. Arikan AA, Zappitelli M, Goldstein SL, et al.Fluid overload is associated with impaired oxygenation and morbidity in critically ill children. Pediatr Crit Care Med. 2012;13:253–258.
    1. Neuen BL, Young T, Heerspink HJL, et al.SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845–854.
    1. Ostermann M, Chawla LS, Forni LG, et al.Drug management in acute kidney disease—Report of the Acute Disease Quality Initiative XVI meeting. Br J Clin Pharmacol. 2018;84:396–403.
    1. Kellum JA, Prowle JR. Paradigms of acute kidney injury in the intensive care setting. Nat Rev Nephrol. 2018;14:217–230.
    1. Radhakrishnan J, Perazella MA. Drug-induced glomerular disease: attention required! Clin J Am Soc Nephrol. 2015;10:1287–1290.
    1. Perazella MA. Drug use and nephrotoxicity in the intensive care unit. Kidney Int. 2012;81:1172–1178.
    1. McCullough PA, Shaw AD, Haase M, et al.Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol. 2013;182:13–29.
    1. Jones M, Tomson C. Acute kidney injury and ‘nephrotoxins’: mind your language. Clin Med (Lond). 2018;18:384–386.
    1. Wu H, Huang J. Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies. Curr Drug Metab. 2018;19:559–567.
    1. Karino S, Kaye KS, Navalkele B, et al.Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin-tazobactam: opportunities for antimicrobial stewardship. Antimicrob Agents Chemother. 2016;60:3743–3750.
    1. Kane-Gill SL, Goldstein SL. Drug-induced acute kidney injury: a focus on risk assessment for prevention. Crit Care Clin. 2015;31:675–684.
    1. Rivosecchi RM, Kellum JA, Dasta JF, et al.Drug class combination-associated acute kidney injury. Ann Pharmacother. 2016;50:953–972.
    1. Lapi F, Azoulay L, Yin H, et al.Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.
    1. Weisbord SD, Gallagher M, Jneid H, et al.Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378:603–614.
    1. Brar SS, Aharonian V, Mansukhani P, et al.Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet. 2014;383:1814–1823.
    1. McDonald JS, McDonald RJ, Williamson EE, et -contrast acute kidney injury in intensive care unit patients: a propensity score-adjusted study. Intensive Care Med. 2017;43:774–784.
    1. Levey AS, Eckardt K-U, Dorman NM, et al.Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020;97:1117–1129.
    1. Wald R, Adhikari NK, Smith OM, et al.Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney Int. 2015;88:897–904.
    1. Karvellas CJ, Farhat MR, Sajjad I, et al.A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. Crit Care. 2011;15:R72.
    1. Wierstra BT, Kadri S, Alomar S, et al.The impact of “early” versus “late” initiation of renal replacement therapy in critical care patients with acute kidney injury: a systematic review and evidence synthesis. Crit Care. 2016;20:122.
    1. Vaara ST, Reinikainen M, Wald R, et al.Timing of RRT based on the presence of conventional indications. Clin J Am Soc Nephrol. 2014;9:1577–1585.
    1. Shiao CC, Wu VC, Li WY, et al.Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery. Crit Care. 2009;13:R171.
    1. Chou YH, Huang TM, Wu VC, et al.Impact of timing of renal replacement therapy initiation on outcome of septic acute kidney injury. Crit Care. 2011;15:R134.
    1. Jun M, Bellomo R, Cass A, et al.Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal versus augmented level of replacement therapy study. Crit Care Med. 2014;42:1756–1765.
    1. Bagshaw SM, Adhikari NKJ, Burns KEA, et al.Selection and receipt of kidney replacement in critically ill older patients with AKI. Clin J Am Soc Nephrol. 2019;14:496–505.
    1. Macedo E, Mehta RL. When should renal replacement therapy be initiated for acute kidney injury? Semin Dial. 2011;24:132–137.
    1. Ostermann M, Joannidis M, Pani A, et al.Patient selection and timing of continuous renal replacement therapy. Blood Purif. 2016;42:224–237.
    1. Wilson FP, Yang W, Machado CA, et al.Dialysis versus nondialysis in patients with AKI: a propensity-matched cohort study. Clin J Am Soc Nephrol. 2014;9:673–681.
    1. Klein SJ, Brandtner AK, Lehner GF, et al.Biomarkers for prediction of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. Intensive Care Med. 2018;44:323–336.
    1. Rewa OG, Bagshaw SM, Wang X, et al.The furosemide stress test for prediction of worsening acute kidney injury in critically ill patients: a multicenter, prospective, observational study. J Crit Care. 2019;52:109–114.
    1. Lumlertgul N, Peerapornratana S, Trakarnvanich T, et al.Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Crit Care. 2018;22:101.
    1. Obrador GT, Rubilar X, Agazzi E, et al.The challenge of providing renal replacement therapy in developing countries: the Latin American perspective. Am J Kidney Dis. 2016;67:499–506.
    1. Ponce D, Buffarah MB, Goes C, et al.Peritoneal dialysis in acute kidney injury: trends in the outcome across time periods. PLoS One. 2015;10:e0126436.
    1. George J, Varma S, Kumar S, et al.Comparing continuous venovenous hemodiafiltration and peritoneal dialysis in critically ill patients with acute kidney injury: a pilot study. Perit Dial Int. 2011;31:422–429.
    1. Esezobor CI, Ladapo TA, Lesi FE. Peritoneal dialysis for children with acute kidney injury in Lagos, Nigeria: experience with adaptations. Perit Dial Int. 2014;34:534–538.
    1. Kelly YP, Mendu ML. Vascular access for renal replacement therapy in acute kidney injury: are nontunneled catheters the right choice? Semin Dial. 2019;32:406–410.
    1. Gattas DJ, Rajbhandari D, Bradford C, et al.A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Crit Care Med. 2015;43:1622–1629.
    1. Liu C, Mao Z, Kang H, et al.Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care. 2016;20:144.
    1. Bai M, Zhou M, He L, et al.Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med. 2015;41:2098–2110.
    1. Bagshaw SM, Chakravarthi MR, Ricci Z, et al.Precision continuous renal replacement therapy and solute control. Blood Purif. 2016;42:238–247.
    1. Bouchard J, Macedo E, Mehta RL. Dosing of renal replacement therapy in acute kidney injury: lessons learned from clinical trials. Am J Kidney Dis. 2010;55:570–579.
    1. Claure-Del Granado R, Macedo E, Chertow GM, et al.Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis. Clin J Am Soc Nephrol. 2011;6:467–475.
    1. Lyndon WD, Wille KM, Tolwani AJ. Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrol Dial Transplant. 2012;27:952–956.
    1. Murugan R, Balakumar V, Kerti SJ, et ultrafiltration intensity and mortality in critically ill patients with fluid overload. Crit Care. 2018;22:223.
    1. Murugan R, Kerti SJ, Chang CH, et al.Association of net ultrafiltration rate with mortality among critically ill adults with acute kidney injury receiving continuous venovenous hemodiafiltration: a secondary analysis of the Randomized Evaluation of Normal vs Augmented Level (RENAL) of Renal Replacement Therapy trial. JAMA Netw Open. 2019;2:e195418.
    1. Chen H, Yu RG, Yin NN, et al.Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy in critically ill patients: a systematic review. Crit Care. 2014;18:675.
    1. Allardet-Servent J, Castanier M, Signouret T, et al.Safety and efficacy of combined extracorporeal CO2 removal and renal replacement therapy in patients with acute respiratory distress syndrome and acute kidney injury: The Pulmonary and Renal Support in Acute Respiratory Distress Syndrome Study. Crit Care Med. 2015;43:2570–2581.
    1. Peperstraete H, Eloot S, Depuydt P, et al.Low flow extracorporeal CO2 removal in ARDS patients: a prospective short-term crossover pilot study. BMC Anesthesiol. 2017;17:155.
    1. Suga N, Matsumura Y, Abe R, et al.A safe procedure for connecting a continuous renal replacement therapy device into an extracorporeal membrane oxygenation circuit. J Artif Organs. 2017;20:125–131.
    1. Askenazi DJ, Selewski DT, Paden ML, et al.Renal replacement therapy in critically ill patients receiving extracorporeal membrane oxygenation. Clin J Am Soc Nephrol. 2012;7:1328–1336.
    1. Fleming GM, Askenazi DJ, Bridges BC, et al.A multicenter international survey of renal supportive therapy during ECMO: the Kidney Intervention During Extracorporeal Membrane Oxygenation (KIDMO) Group. ASAIO J. 2012;58:407–414.
    1. Forster C, Schriewer J, John S, et al.Low-flow CO(2) removal integrated into a renal-replacement circuit can reduce acidosis and decrease vasopressor requirements. Crit Care. 2013;17:R154.
    1. May AG, Sen A, Cove ME, et al.Extracorporeal CO2 removal by hemodialysis: in vitro model and feasibility. Intensive Carne Med Exp. 2017;5:20.
    1. Vu LH, Kellum JA, Federspiel WJ, et al.Carbon dioxide removal using low bicarbonate dialysis in rodents. Perfusion. 2019, 267659119839284.
    1. Fanelli V, Cantaluppi V, Alessandri F, et al.Extracorporeal CO2 removal may improve renal function of patients with acute respiratory distress syndrome and acute kidney injury: an open-label, interventional clinical trial. Am J Respir Crit Care Med. 2018;198:687–690.
    1. Ostermann M, Connor M Jr, Kashani K. Continuous renal replacement therapy during extracorporeal membrane oxygenation: why, when and how? Curr Opin Crit Care. 2018;24:493–503.
    1. Seczynska B, Krolikowski W, Nowak I, et al.Continuous renal replacement therapy during extracorporeal membrane oxygenation in patients treated in medical intensive care unit: technical considerations. Ther Apher Dial. 2014;18:523–534.
    1. Zhou XL, Chen YH, Wang QY. A new approach combining venoarterial extracorporeal membrane oxygenation and CRRT for adults: a retrospective study. Int J Artif Organs. 2017;40:345–349.
    1. de Tymowski C, Augustin P, Houissa H, et al.CRRT connected to ECMO: managing high pressures. ASAIO J. 2017;63:48–52.
    1. Shum HP, Kwan AM, Chan KC, et al.The use of regional citrate anticoagulation continuous venovenous hemofiltration in extracorporeal membrane oxygenation. ASAIO J. 2014;60:413–418.
    1. Husain-Syed F, Ricci Z, Brodie D, et al.Extracorporeal organ support (ECOS) in critical illness and acute kidney injury: from native to artificial organ crosstalk. Intensive Care Med. 2018;44:1447–1459.
    1. Schneider AG, Bellomo R, Bagshaw SM, et al.Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis. Intensive Care Med. 2013;39:987–997.
    1. Truche AS, Darmon M, Bailly S, et al.Continuous renal replacement therapy versus intermittent hemodialysis in intensive care patients: impact on mortality and renal recovery. Intensive Care Med. 2016;42:1408–1417.
    1. Liang KV, Sileanu FE, Clermont G, et al.Modality of RRT and recovery of kidney function after AKI in patients surviving to hospital discharge. Clin J Am Soc Nephrol. 2016;11:30–38.
    1. Neyra JA, Li X, Yessayan L, et al.Dipstick albuminuria and acute kidney injury recovery in critically ill septic patients. Nephrology (Carlton). 2016;21:512–518.
    1. Lim CT, Tan HK, Lau YK. The significance of tubular and glomerular proteinuria in critically ill patients with severe acute kidney injury. Pak J Med Sci. 2014;30:1186–1190.
    1. Hsu CY, Chinchilli VM, Coca S, et -acute kidney injury proteinuria and subsequent kidney disease progression: the Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study. JAMA Intern Med. 2020;180:402–410.
    1. Thakar CV, Parikh PJ, Liu Y. Acute kidney injury (AKI) and risk of readmissions in patients with heart failure. Am J Cardiol. 2012;109:1482–1486.
    1. Wang Y, Gallagher M, Li Q, et al.Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: a systematic review and individual patient data meta-analysis. Nephrol Dial Transplant. 2018;33:1017–1024.
    1. De Corte W, Dhondt A, Vanholder R, et al.Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study. Crit Care. 2016;20:256.
    1. Mottes TA, Goldstein SL, Basu RK. Process based quality improvement using a continuous renal replacement therapy dashboard. BMC Nephrol. 2019;20:17.
    1. Rewa OG, Tolwani A, Mottes T, et al.Quality of care and safety measures of acute renal replacement therapy: workgroup statements from the 22nd acute disease quality initiative (ADQI) consensus conference. J Crit Care. 2019;54:52–57.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する